Proton Therapy Partners is pleased to announce that it has named Christopher Dodge as Vice President of Business Development. As a senior healthcare sales and marketing executive, Chris has over 25 years of leadership experience in the radiation oncology market. The past four years he served as Vice President of Business Development and Customer Financing at Mevion Medical Systems, a global leader in Compact Proton Therapy solutions. Prior to Mevion, Dodge spent 15 years at radiation oncology market leader, Varian Medical Systems, holding multiple senior positions, most recently as Senior Sales Director, Varian Delivery Systems with responsibility for linear accelerator and all other hardware sales in the North America’s region. Chris brings to Proton Therapy Partners his expertise in External Beam Radiation Delivery including Stereotactic Radiosurgery, SBRT, and Proton Therapy, as well as his experience in value-based healthcare, strategic account development, healthcare funding, and developing win/win clinical and economic solutions for healthcare providers. Dodge is a graduate of The University of Virginia, McIntire School of Commerce.
“Proton Therapy Partners is extremely excited about having such a seasoned and accomplished healthcare executive join our growing team of experts,” says Christopher M. Dadlez, FACHE, President & CEO of PTP. “He has an exceptional passion for making proton therapy accessible to all cancer patients who can benefit from this advanced and important treatment”.
“I am very excited to be joining the Proton Therapy Partners team,” says Dodge. “PTP is quickly establishing itself as an industry leader in both proton project development and in providing a unique funding strategy that addresses the economic concerns that have to date challenged the expansion of proton therapy into many markets. All patients deserve access to proton therapy.”